BioLineRx (BLRX) Long-Term Debt Issuances (2021 - 2025)

BioLineRx's Long-Term Debt Issuances history runs 5 years deep, the most recent figure standing at -$1.1 million for Q4 2025.

• On a quarterly basis, Long-Term Debt Issuances rose 90.49% year-over-year to -$1.1 million in Q4 2025; TTM through Dec 2025 was -$4.5 million, a 68.84% increase from a year earlier, with the FY2025 full-year figure at -$4.5 million, up 68.84% from the prior year.
• Long-Term Debt Issuances slipped to -$1.1 million in Q4 2025 per BLRX's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at -$741000.0 in Q4 2023 and bottomed at -$12.0 million in Q4 2024.
• The 5-year median for Long-Term Debt Issuances is -$904500.0 (2022), against an average of -$1.6 million.
• Across the five-year window, Long-Term Debt Issuances sank 1515.65% in 2024 and jumped 90.49% in 2025, its largest moves.
• Year by year, Long-Term Debt Issuances stood at -$854000.0 in 2021, then fell by 19.44% to -$1.0 million in 2022, then climbed by 27.35% to -$741000.0 in 2023, then sank by 1515.65% to -$12.0 million in 2024, then soared by 90.49% to -$1.1 million in 2025.
• Per Business Quant, the three latest BLRX Long-Term Debt Issuances figures stand at -$1.1 million (Q4 2025), -$1.1 million (Q3 2025), and -$1.1 million (Q2 2025).